Clinical trial
Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic…
NCT00314782 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00314782 |
|---|---|
| Title | Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC |
| Official title | A Phase I Study of ZD4054 (Zibotentan) in Combination With Docetaxel in 2 Parts, an Open-Label, Non-Randomized, Dose-Finding Part and a Double-Blind, Placebo-Controlled, Randomized Dose Expansion Part, in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | ZD4054 (Zibotentan), Docetaxel, Placebo |
| Enrollment | 44 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Apr 17, 2006 |
| Last update posted | Mar 12, 2013 |
| Countries | Germany, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: